Dr. Scott Solomon: Dapagliflozin Benefits Patients With Heart Failure, Kidney Disease

A pooled analysis from the DELIVER and DAPA-HF trials assessed the efficacy of FARXIGA (dapagliflozin) in patients with heart failure and deteriorating kidney function. The findings, which demonstrated clinical benefit, were presented at the European Society of Cardiology Congress 2023.

In this exclusive interview, DocWire News spoke with the presenting investigator, Dr. Scott Solomon, of Brigham and Women’s Hospital and Harvard Medical School, about the results and how they reinforce the connection between heart failure and kidney disease and the benefit of treatment with dapagliflozin.